A “Game of Thrones” in Metastatic Renal Cell Carcinoma: Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors and Mammalian Target of Rapamycin Inhibitors Battling for Position

Similar Items

• Mammalian target of rapamycin, Akt, and phosphatidylinositol 3-kinase signaling
  od: Pal, Sumanta K., i dr.
  Izdano: (2010)
• Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma
  od: Pal, Sumanta Kumar, i dr.
  Izdano: (2011)
• Game of Thrones
  od: Revolon, Sandra
  Izdano: (2020)
• Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implications
  od: Aslam, Shahzeena, i dr.
  Izdano: (2013)
• Outcomes of Unselected Patients with Metastatic Clear-Cell Renal Cell Carcinoma Treated with Front-Line Pazopanib Therapy Followed by Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors (VEGFR-TKI) or Mammalian Target of Rapamycin Inhibitors (mTORi): A Single Institution Experience
  od: Matrana, Marc R., i dr.
  Izdano: (2015)